| Market Cap | 44.79M | P/E | - | EPS this Y | 57.50% | Ern Qtrly Grth | - |
| Income | -34.44M | Forward P/E | -1.58 | EPS next Y | 24.60% | 50D Avg Chg | -5.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -30.00% |
| Dividend | N/A | Price/Book | 3.40 | EPS next 5Y | - | 52W High Chg | -72.00% |
| Recommedations | 1.70 | Quick Ratio | 0.76 | Shares Outstanding | 64.33M | 52W Low Chg | 35.00% |
| Insider Own | 0.24% | ROA | -129.15% | Shares Float | 64.15M | Beta | 2.40 |
| Inst Own | 9.54% | ROE | -888.06% | Shares Shorted/Prior | 8.16M/7.72M | Price | 1.58 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 154,591 | Target Price | 5.83 |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 138,762 | Change | -3.66% |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.